Type 2 diabetes. Non-insulin-dependent diabetes mellitus
Conditions
Interventions
Treatment - Drugs
Placebo
Sponsors
Vice chancellor of Research, Tehran University of Medical Sciences
Diabetes Research Center, Endocrinology and Metabolism research Institute, Tehran University of Medi
Eligibility
Sex/Gender
All
Age
40 Years to 60 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: Ability to give informed consent; Age 40-60 years; Diabetic patients with BMI less than 35 kg/m2; Lack of insulin therapy; HbA1c > 7.5. Exclusion criteria: Subjects on any antioxidant medication; Patient on non-steroidal anti-inflammatory drug; Patients on insulin therapy; Patients with severe diabetic complications such as nephropathy , retinopathy and amputation; On any agent with significant antioxidant properties; History of alcohol abuse; Any life threatening disease such as cancer and infectious diseases; Allergy to peanuts, grapes, wine, mulberries; Pregnant women; Coronary event or procedure (myocardial infarction, unstable angina, coronary artery bypass surgery or coronary angioplasty) in the previous four weeks; Subjects on anticoagulants; History of recent taking red grapes, pistachios, almonds and berries; ALT and/or AST > 2 times above upper limit of normal.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HbA1c. Timepoint: Before and two months after intervention. Method of measurement: HPLC.;FBS. Timepoint: Before and two months after intervention. Method of measurement: Enzymatic reaction.;Reactive oxygen species (ROS). Timepoint: Before and two months after intervention. Method of measurement: Flow cytometry. | — |
Secondary
| Measure | Time frame |
|---|---|
| HDL. Timepoint: Before and two months after intervention. Method of measurement: Spectrophotometry.;LDL. Timepoint: Before and two months after intervention. Method of measurement: Spectrophotometry.;Insulin. Timepoint: Before and two months after intervention. Method of measurement: ELISA Kit.;Cholesterol. Timepoint: Before and two months after intervention. Method of measurement: Spectrophotometry.;Triglyceride. Timepoint: Before and two months after intervention. Method of measurement: Spectrophotometry.;ALT. Timepoint: Before and two months after intervention. Method of measurement: Spectrophotometry.;AST. Timepoint: Before and two months after intervention. Method of measurement: Spectrophotometry.;Insulin resistance. Timepoint: Before and two months after intervention. Method of measurement: HOMA-IR.;CRP. Timepoint: Before and two months after intervention. Method of measurement: ELISA Kit.;Creatinine. Timepoint: Before and two months after intervention. Method of measurement: Spectrophotometry.;Urea. Timepoint: Before and two months after intervention. Method of measurement: Spectrophotometry.;BMI. Timepoint: Before and two months after intervention. Method of measurement: the formula for BMI is weight in kilograms divided by height in meters squared.;Diastolic and systolic blood pressure. Timepoint: Before and two months after intervention. Method of measurement: Sphygmomanometer and Stethoscope will be used to measure the blood pressure.;Glutathione. Timepoint: Before and two months after intervention. Method of measurement: Spectrophotometry.;Malondialdehyde (MDA). Timepoint: Before and two months after intervention. Method of measurement: Spectrophotometry.;Plasma protein carbonyl. Timepoint: Before and two months after intervention. Method of measurement: Spectrophotometry.;Total antioxidant capacity. Timepoint: Before and two months after intervention. Method of measurement: Spectrophotometry.;Expression of Sirt1. Timepoint: Before and two months after | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactShadi Seyyed Ebrahimi
Tehran University of Medical Sciences
Outcome results
None listed